Literature DB >> 29790163

Predictors of new-onset chronic kidney disease in patients managed surgically for T1a renal cell carcinoma: An Australian population-based analysis.

Thomas Ahn1, Robert J Ellis1,2,3,4, Victoria M White5,6, Damien M Bolton7,8, Michael D Coory8, Ian D Davis9,10, Ross S Francis1,3, Graham G Giles5,8, Glenda C Gobe1,3,4, Carmel M Hawley1,3,4, David W Johnson1,3,4, David J T Marco8, Megan McStea3,4, Rachel E Neale2, Elaine M Pascoe3,4, Simon T Wood1,3,4, Susan J Jordan2,3.   

Abstract

BACKGROUND: New-onset chronic kidney disease (CKD) following surgical management of kidney tumors is common. This study evaluated risk factors for new-onset CKD after nephrectomy for T1a renal cell carcinoma (RCC) in an Australian population-based cohort.
METHODS: There were 551 RCC patients from the Australian states of Queensland and Victoria included in this study. The primary outcome was new-onset CKD (eGFR <60 mL/min per 1.73 m2 ) and the secondary outcome was new-onset moderate-severe CKD (<45 mL/min per 1.73 m2 ). Multivariable logistic regression was used to evaluate associations between patient, tumor and health-service characteristics and these outcomes.
RESULTS: Forty percent (219/551) of patients developed new-onset CKD, and 12% (68/551) experienced new-onset moderate-severe CKD. Risk factors for new-onset CKD were age, lower preoperative eGFR, tumor size >20 mm, radical nephrectomy, lower hospital caseloads (<20 cases/year), and rural place of residence. The associations between rural place of residence and low center volume were a consequence of higher radical nephrectomy rates.
CONCLUSION: Risk factors for CKD after nephrectomy generally relate to worse baseline health, or likelihood of undergoing radical nephrectomy. Surgeons in rural centres and hospitals with low caseloads may benefit from formalized integration with specialist centers for continued professional development and case-conferencing, to assist in management decisions.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic kidney disease; estimated glomerular filtration rate; nephrectomy; renal cell carcinoma

Mesh:

Year:  2018        PMID: 29790163     DOI: 10.1002/jso.25037

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  End-Stage Kidney Disease following Surgical Management of Kidney Cancer.

Authors:  Robert J Ellis; Daniel P Edey; Sharon J Del Vecchio; Megan McStea; Scott B Campbell; Carmel M Hawley; David W Johnson; Christudas Morais; Susan J Jordan; Ross S Francis; Simon T Wood; Glenda C Gobe
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-28       Impact factor: 8.237

2.  Development and Validation of a Nomogram Model to Predict Acute Kidney Disease After Nephrectomy in Patients with Renal Cell Carcinoma.

Authors:  Xiao-Ying Hu; Dong-Wei Liu; Ying-Jin Qiao; Xuan Zheng; Jia-Yu Duan; Shao-Kang Pan; Zhang-Sou Liu
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

Review 3.  Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms.

Authors:  Mengsi Hu; Qianhui Wang; Bing Liu; Qiqi Ma; Tingwei Zhang; Tongtong Huang; Zhimei Lv; Rong Wang
Journal:  Front Cell Dev Biol       Date:  2022-05-18

Review 4.  Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome.

Authors:  Simona Mihai; Elena Codrici; Ionela Daniela Popescu; Ana-Maria Enciu; Lucian Albulescu; Laura Georgiana Necula; Cristina Mambet; Gabriela Anton; Cristiana Tanase
Journal:  J Immunol Res       Date:  2018-09-06       Impact factor: 4.818

5.  Tumor size and postoperative kidney function following radical nephrectomy.

Authors:  Robert J Ellis; Victoria M White; Damien M Bolton; Michael D Coory; Ian D Davis; Ross S Francis; Graham G Giles; Glenda C Gobe; Rachel E Neale; Simon T Wood; Susan J Jordan
Journal:  Clin Epidemiol       Date:  2019-05-06       Impact factor: 4.790

6.  A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy: Development and Multinational Validation.

Authors:  Robert J Ellis; Sharon J Del Vecchio; Kevin M J Gallagher; Danielle N Aliano; Neil Barber; Damien M Bolton; Etienne T S Chew; Jeff S Coombes; Michael D Coory; Ian D Davis; James F Donaldson; Ross S Francis; Graham G Giles; Glenda C Gobe; Carmel M Hawley; David W Johnson; Alexander Laird; Steve Leung; Manar Malki; David J T Marco; Alan S McNeill; Rachel E Neale; Keng L Ng; Simon Phipps; Grant D Stewart; Victoria M White; Simon T Wood; Susan J Jordan
Journal:  J Am Soc Nephrol       Date:  2020-04-01       Impact factor: 10.121

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.